A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs). The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle. The complexes formed by CDK4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase. CDK4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen and a protein, p21 (refs 7-9). CDK4 associates separately with a protein of M(r) 16K, particularly in cells lacking a functional retinoblastoma protein. Here we report the isolation of a human p16 complementary DNA and demonstrate that p16 binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. p16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p16, on the other hand, acts through the Retinoblastoma (Rb) pathway (Serrano et al, 1993).”
From Distinct senotypes in p16- and p21-positive cells across human and mouse aging tissues (2025) · cites this paper as Serrano et al, 1993
In the citing paper
“p16INK4A is a 16 KDa protein that directly binds to CDK4/6 and blocks the formation of cyclinD-CDK4/6 complexes, thereby preventing phosphorylation of RB and promoting expression of E2F target genes (Serrano et al., 1993).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Serrano et al., 1993
In the citing paper
“This member of the INK4a family is a cyclin D-dependent kinase CDK4 and CDK6 inhibitor, which prevents the phosphorylation of the retinoblastoma protein (Rb), therefore leading to suspension of the cell cycle before the S-phase [78,79].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [78]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
A novel genetic system to detect protein–protein interactions
Fields, S., & Song, O.-K. (1989) · Nature · doi:10.1038/340245a0 · Cited by 6,114
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Self-citationSherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
Self-citationFunctional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
A family of human cdc2-related protein kinases.
Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., Harlow, E., & Tsai, L. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 923
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Research works printed but not linked: 2
- Motokura, T. & Arnold, A. Biochim. biophys. Acta 1155, 63–78 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene (in the press).
Cited by
Items 201–300 of 1,022
Chang, M. W., Barr, E., Lu, M. M., Barton, K., & Leiden, J. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118281 · Cited by 354
“The kinase activities of the cyclinD/CDK complexes can themselves be negatively regulated by several different molecules including p16, p21, and p27 (16-23).”
BackgroundRobertson, K. D., & Jones, P. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6457 · Cited by 352
Ultraviolet radiation and skin cancer: molecular mechanisms
Hussein, M. R. (2005) · Journal of Cutaneous Pathology · doi:10.1111/j.0303-6987.2005.00281.x · Cited by 352
Zhang, H. S., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)80714-x · Cited by 349
Zhang, Y., & Xiong, Y. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80351-2 · Cited by 348
“INK4a (Serrano et al., 1993), while the exon 1b–exon 2–exon 3 transcript specifies ARF in an alternative read- Results ing frame, which results in a protein bearing no amino acid sequence similarity to INK4a (Quelle et al.”
BackgroundInfluentialProliferative capacity of corneal endothelial cells
Joyce, N. C. (2012) · Experimental Eye Research · doi:10.1016/j.exer.2011.08.014 · Cited by 347
“The “INK” family includes p16INK4a, which specifically binds to free CDK4 and prevents its association with cyclin D to form an active complex (Serrano et al., 1993).”
BackgroundBorg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., Westerdahl, J., Olsson, H., & Ingvar, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1260 · Cited by 345
“Both mutations reside in the fourth ankyrin repeat region, which is assumed to be involved in cdk4/cdk6 binding ( 3 ).”
BackgroundCellular senescence in renal ageing and disease
Sturmlechner, I., Durik, M., Sieben, C. J., Baker, D. J., & van Deursen, J. M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.183 · Cited by 345
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
A Viral Mechanism for Inhibition of p300 and PCAF Acetyltransferase Activity
Chakravarti, D., Ogryzko, V., Kao, H.-Y., Nash, A., Chen, H., Nakatani, Y., & Evans, R. M. (1999) · Cell · doi:10.1016/s0092-8674(00)80552-8 · Cited by 339
Quesnel, B., Guillerm, G., Vereecque, R., Wattel, E., Preudhomme, C., Bauters, F., Vanrumbeke, M., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.8.2985.2985_2985_2990 · Cited by 342
“5 (16-87) 26 M, 27 F 11 (1-85) 15/44 (9 ND) 20 (38)”
Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J. J., Richards, W. G., Sugarbaker, D. J., & Rollins, B. J. (1995) · PubMed · Cited by 376
Rheinwald, J. G., Hahn, W. C., Ramsey, M. R., Wu, J. Y., Guo, Z., Tsao, H., De Luca, M., Catricalà, C., & O'Toole, K. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5157-5172.2002 · Cited by 338
“For keratinocytes (17, 31), mammary epithelial cells (11, 21, 31, 56), bladder urothelial cells (51), and prostate epithelial cells (28, 57), senescence has been found to be associated with expression and accumulation of high levels of p16, an inhibitor of cdk4 and cdk6 (48, 59).”
BackgroundNon-melanoma skin cancer: what drives tumor development and progression?
Boukamp, P. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi123 · Cited by 338
“A role for cell cycle inhibitors One cell cycle inhibitor that is playing an important role in epithelial transformation is the cyclin-dependent kinase inhibitor p16 that specifically inhibits progression through G1 phase of the cell cycle by blocking the cyclin-dependent kinase 4 from phosphorylating the retinoblasto…”
Identification of Human and Mouse p19, a Novel CDK4 and CDK6 Inhibitor with Homology to p16ink4
Chan, F. K. M., Zhang, J., Cheng, L., Shapiro, D. N., & Winoto, A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2682 · Cited by 339
“Their inhibitory activity is restricted to the cyclin D-CDK4 and cyclin D-CDK6 kinases (7, 30).”
BackgroundMethodInfluentialRegulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to Cancer
Li, J., Poi, M. J., & Tsai, M.-D. (2011) · Biochemistry · doi:10.1021/bi200642e · Cited by 334
Reynisdóttir, I., & Massagué, J. (1997) · Genes & Development · doi:10.1101/gad.11.4.492 · Cited by 333
Mateyak, M. K., Obaya, A. J., & Sedivy, J. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4672 · Cited by 331
Lukas, J., Bartkova, J., & Bartek, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6917 · Cited by 327
“MCF-7 cells stimulated by each of the three protocols were microinjected in early G1, within 2 to 4 h poststimulation, with either the cyclin D1-neutralizing monoclonal antibody DCS-6 (34, 37) or the GST-p16 fusion protein known to inhibit cyclin D-associated cdk4 or cdk6 (28, 33, 38, 52, 59 ), and the effects of thes…”
BackgroundMethodKim, D. H., Nelson, H. H., Wiencke, J. K., Zheng, S., Christiani, D. C., Wain, J. C., Mark, E. J., & Kelsey, K. T. (2001) · PubMed · Cited by 365
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
Smalley, K. S. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.10978 · Cited by 325
Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma
Begum, S., Cao, D., Gillison, M., Zahurak, M., & Westra, W. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0587 · Cited by 325
Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation
Sielecki, T. M., Boylan, J. F., Benfield, P. A., & Trainor, G. L. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990256j · Cited by 323
The INK4 family of cell cycle inhibitors in cancer
Roussel, M. F. (1999) · Oncogene · doi:10.1038/sj.onc.1202998 · Cited by 322
“Since the discovery of p16INK4a (Serrano et al., 1993) and p21CIP1 (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993), the cyclin-dependent kinase inhibitors (CKIs) have been intensively investigated.”
BackgroundCyclin-Binding Motifs Are Essential for the Function of p21 CIP1
Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D., & Dutta, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4673 · Cited by 320
“pGST-cyclin E (1-127) was generated by removing the PstIHindIII fragment from pGST-cyclin E.”
BackgroundMethodInfluentialCdk inhibitors: on the threshold of checkpoints and development
Elledge, S. J., & Harper, J. W. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90055-8 · Cited by 320
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.
Ponce-Castañeda, M. V., Lee, M.-H., Latres, E., Polyák, K., Lacombe, L., Montgomery, K., Mathew, S., Krauter, K., Sheinfeld, J., & Massagué, J. (1995) · PubMed · Cited by 354
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.
Cheng, J. Q., Jhanwar, S., Klein, W. M., Bell, D. W., Lee, W.-C., Altomare, D. A., Nobori, T., Olopade, O. I., Buckler, A., & Testa, J. R. (1994) · PubMed · Cited by 319
Lambert, J.-P., Ivosev, G., Couzens, A. L., Larsen, B., Taipale, M., Lin, Z.-Y., Zhong, Q., Lindquist, S., Vidal, M., Aebersold, R., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2702 · Cited by 318
de Nooij, J. C., Letendre, M. A., & Hariharan, I. K. (1996) · Cell · doi:10.1016/s0092-8674(00)81819-x · Cited by 318
A critical role for telomeres in suppressing and facilitating carcinogenesis
Artandi, S. E., & DePinho, R. A. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00047-7 · Cited by 318
P16 gene in uncultured tumours
Spruck, C. H., Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M.-F., Gonzales, F., Tsai, Y. C., & Jones, P. A. (1994) · Nature · doi:10.1038/370183a0 · Cited by 318
Bruggeman, S. W. M., Valk-Lingbeek, M. E., van der Stoop, P. P. M., Jacobs, J. J. L., Kieboom, K., Tanger, E., Hulsman, D., Leung, C., Arsenijevic, Y., Marino, S., et al. (2005) · Genes & Development · doi:10.1101/gad.1299305 · Cited by 315
“The Ink4a/Arf locus codes for two proteins, p16ink4a and p19arf (Ink4a and Arf), by use of alternative reading frames (Serrano et al. 1993; Quelle et al. 1995).”
BackgroundCells exhibiting strong p16 INK4a promoter activation in vivo display features of senescence
Liu, J.-Y., Souroullas, G. P., Diekman, B. O., Krishnamurthy, J., Hall, B. M., Sorrentino, J. A., Parker, J. S., Sessions, G. A., Gudkov, A. V., & Sharpless, N. E. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818313116 · Cited by 306
“As a cell cycle regulator, p16 limits G1 to S-phase progression of the cell cycle through inhibition of the CDK4 and CDK6 (CDK4/6) kinases (7).”
BackgroundMolecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.
Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J. F., & Wilcyznski, S. (1995) · PubMed · Cited by 340
MC1R Genotype Modifies Risk of Melanoma in Families Segregating CDKN2A Mutations
Box, N. F., Duffy, D. L., Chen, W., Stark, M., Martin, N. G., Sturm, R. A., & Hayward, N. K. (2001) · The American Journal of Human Genetics · doi:10.1086/323412 · Cited by 310
“G1-S phase transition is usually dependent upon phosphorylation of the retinoblastoma protein (pRB) by the cyclin D1/CDK4 complex (Serrano et al. 1993; Lukas et al. 1995).”
BackgroundHomozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., & Frants, R. R. (1995) · Nature Genetics · doi:10.1038/ng0795-351 · Cited by 310
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Begum, S., Gillison, M. L., Ansari-Lari, M. A., Shah, K. V., & Westra, W. H. (2003) · PubMed · Cited by 307
Laronga, C., Yang, H.-Y., Neal, C., & Lee, M.-H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m905616199 · Cited by 304
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Fabbri, G., Khiabanian, H., Holmes, A. B., Wang, J., Messina, M., Mullighan, C. G., Pasqualucci, L., Rabadan, R., & Dalla-Favera, R. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131448 · Cited by 302
Interaction mating reveals binary and ternary connections between Drosophila cell cycle regulators.
Finley, R. L., & Brent, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12980 · Cited by 303
Novitch, B. G., Mulligan, G. J., Jacks, T., & Lassar, A. B. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.2.441 · Cited by 304
“A role for cyclin D--dependent kinases in controlling MyoD function is supported by the finding that ectopic expression of p16, a specific inhibitor of cyclin-D/Cdk4 and Cdk6 kinases (Serrano et al., 1993), or p21, a more universal inhibitor of cyclin-dependent kinases (Cdks) (Gu et al.”
BackgroundThe genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
Multistep carcinogenesis of breast cancer and tumour heterogeneity
Beckmann, M. W., Niederacher, D., Schnürch, H.-G., Gusterson, B. A., & Bender, H. G. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050128 · Cited by 299
Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S. S., Gaudin, P. B., Fazzari, M., Zhang, Z.-F., Massague, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.17.1284 · Cited by 300
“The INK group includes four members: p16INK4A/MTS1/CDKN2 ( 13 ), p15INK4B/MTS2 (14), p18INK4C (15), and p19INK4D (16).”
Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase.
Kato, J. Y., Matsuoka, M., Strom, D. K., & Sherr, C. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.4.2713 · Cited by 298
“Alternatively, assembly of the holoenzymes might be prevented by any of a number of recently identified cdk inhibitors, whose interactions with unbound catalytic subunits might prevent their association with cyclins (14, 20, 21, 37, 41, 48-50).”
BackgroundGroshong, S. D., Owen, G. I., Grimison, B., Schauer, I. E., Todd, M. C., Langan, T. A., Sclafani, R. A., Lange, C. A., & Horwitz, K. B. (1997) · Molecular Endocrinology · doi:10.1210/me.11.11.1593 · Cited by 299
Signaling phosphate starvation
LENBURG, M., & OSHEA, E. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10048-7 · Cited by 294
Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts
Pagano, M., Theodoras, A. M., Tam, S. W., & Draetta, G. F. (1994) · Genes & Development · doi:10.1101/gad.8.14.1627 · Cited by 294
The Molecular Balancing Act of p16INK4a in Cancer and Aging
LaPak, K. M., & Burd, C. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 291
“Discovered through homology-based cDNA library screens, p15 functions analogously 20 to p16, directly blocking the interaction of CDK4/6 with D-type cyclins (2, 3).”
Pinyol, M., Cobo, F., Bea, S., Jares, P., Nayach, I., Fernandez, P. L., Montserrat, E., Cardesa, A., & Campo, E. (1998) · Blood · doi:10.1182/blood.v91.8.2977.2977_2977_2984 · Cited by 290
A cell cycle-regulated inhibitor of cyclin-dependent kinases.
Hengst, L., Dulic, V, Slingerland, J. M., Lees, E., & Reed, S. I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5291 · Cited by 287
The INK4a/ARF tumor suppressor: one gene—two products—two pathways
Chin, L., Pomerantz, J., & DePinho, R. A. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01236-5 · Cited by 288
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
Cyclin dependent kinase regulation
Lees, E. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80060-3 · Cited by 285
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 280
“The INK family comprises four structurally related proteins (p16, p15, p18 and p19) 20–22 , with a high affinity for CDK4 and CDK6 relative to other CDK isozymes 20 . p16 is the most widely characterized, and robust p16 upregulation is a hallmark of loss of RB1 function 23,24 .”
Cell-cycle regulators and cancer
Kamb, A. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89027-7 · Cited by 284
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280
Self-citationG‐protein‐coupled receptor for short‐chain fatty acids suppresses colon cancer
Tang, Y., Chen, Y., Jiang, H., Robbins, G. T., & Nie, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25638 · Cited by 281
“p15 and p16 have been shown to be able to specifically inhibit cyclin D/CDK4/6 complexes.(43,44) As shown in Figure 5b, in contrast to the significant downregulation of CDK1/2, we observed only slight changes of CDK4/6 during GPR43/ propionate treatment.”
ResultId proteins in cell cycle control and cellular senescence
Zebedee, Z., & Hara, E. (2001) · Oncogene · doi:10.1038/sj.onc.1205092 · Cited by 282
“In contrast to the Kip/Cip family, which inhibits a broad range of CDKs, the INK4 family protein speci®cally binds to and inactivates CDK4 and CDK6 (Serrano et al., 1993; Ruas and Peters, 1998; Sherr and Roberts, 1999).”
BackgroundInfluentialDNA methyltransferase inhibitors—state of the art
Goffin, J., & Eisenhauer, E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf314 · Cited by 283
“In the absence of p16, phosphorylated Rb allows progression through the cell cycle [40].”
BackgroundSignaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
Hebert, J., Cayuela, J., Berkeley, J., & Sigaux, F. (1994) · Blood · doi:10.1182/blood.v84.12.4038.bloodjournal84124038 · Cited by 281
Schulze‐Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., & Kim, S. (1995) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340220408 · Cited by 279
Kuan, C.-Y., Schloemer, A. J., Lu, A., Burns, K. A., Weng, W.-L., Williams, M. T., Strauss, K. I., Vorhees, C. V., Flavell, R. A., Davis, R. J., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3883-04.2004 · Cited by 280
“To test this possibility and extend our analysis, we examined the expression of another G1-phase CDK2 inhibitor, p16INK4, after hypoxia–ischemia (Serrano et al. 1993).”
Blain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Appay, R., Dehais, C., Maurage, C.-A., Alentorn, A., Carpentier, C., Colin, C., Ducray, F., Escande, F., Idbaih, A., Kamoun, A., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz124 · Cited by 278
Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression
Brewer, J. W., Hendershot, L. M., Sherr, C. J., & Diehl, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8505 · Cited by 276
Multiple functions of p27Kip1 and its alterations in tumor cells: a review
Sgambato, A., Cittadini, A., Faraglia, B., & Weinstein, I. B. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<18::aid-jcp3>3.0.co;2-s · Cited by 276
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bártková, J., Lukáš, J., Guldberg, P., Alsner, J., Kirkin, A. F., Zeuthen, J., & Bártek, J. (1996) · PubMed · Cited by 303
TGF-β-receptor-mediated signaling
Derynck, R. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90059-0 · Cited by 274
Shen, D.-W., Goldenberg, S., Pastan, I., & Gottesman, M. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<108::aid-jcp13>3.0.co;2-4 · Cited by 96
Cell cycle regulted transcription in yeast
Koch, C., & Nasmyth, K. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90039-6 · Cited by 273
Collado, M., Medema, R. H., Garcı́a-Cao, I., Dubuisson, M. L. N., Barradas, M., Glassford, J., Rivas, C., Burgering, B. M. T., Serrano, M., & Lam, E. W.-F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000759200 · Cited by 271
Self-citationLiu, J., Ding, Y., Liu, Z., & Liang, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00258 · Cited by 270
“p16INK4A is an inhibitor of cyclin-dependent kinase (CDK) and induces premature cell senescence via telomere-dependent and -independent mechanisms (Serrano et al., 1993).”
BackgroundSuzuki, T., Kitao, S., Matsushime, H., & Yoshida, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00505.x · Cited by 269
Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, A., & Rajawat, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073553 · Cited by 264
“DDR initiates the stabilization of tumor suppressor, p53 which in turn induces cyclin dependent kinase (CDK) inhibitor (CDKi), p21Cip1, which initiates cell cycle arrest [42,43]. p16INK4a was shown to directly bind and inhibit the catalytic activity of CDK4 [44] and CDK6 [45].”
BackgroundRampias, T., Sasaki, C., Weinberger, P., & Psyrri, A. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp017 · Cited by 264
Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes
Uchida, T., Kinoshita, T., Nagai, H., Nakahara, Y., Saito, H., Hotta, T., & Murate, T. (1997) · Blood · doi:10.1182/blood.v90.4.1403 · Cited by 269
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
“inhibits CDK4/6 activity by maintaining RB1 in its hypophosphorylated, antiproliferative state (41), p14 inhibits HDM2-mediated ubiquitination and subsequent degradation of p53 (42); thus, loss of p14 inactivates p53 (Fig.”
BackgroundLoercher, A. E., Tank, E. M. H., Delston, R. B., & Harbour, J. W. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200410115 · Cited by 266
“Because p16 Ink4a induces a G1 cell cycle arrest by inhibiting Cdk4 and allowing the accumulation of hypophosphorylated retinoblastoma protein (Rb) (Serrano et al., 1993), we examined the Rb protein in 10T1/2 cells after ectopic expression on January 28, 2015 jcb.rupress.org D ow nloaded from MITF…”
BackgroundThe Drosophila Cyclin D-Cdk4 complex promotes cellular growth
Datar, S. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4543 · Cited by 266
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J.-I. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 264
“The TCGA pilot project revealed that the frequency of genetic alterations in the RB signaling pathway was 77%, containing CDKN2A homozygous deletion or mutations (52%), CDKN2B (p15 INK4b ) homozygous deletion (47%), CDKN2C (p18 INK4c ) homozygous deletion (2%), CDK4 amplification (18%), CCND2 (cyclin D2) amplification…”
BackgroundInfluentialNielsen, G. P., Stemmer-Rachamimov, A. O., Ino, Y., Møller, M. B., Rosenberg, A. E., & Louis, D. N. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65507-1 · Cited by 266
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
He, G., Siddik, Z. H., Huang, Z., Wang, R., Koomen, J., Kobayashi, R., Khokhar, A. R., & Kuang, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208474 · Cited by 264
“Finally, although the Cdk4 binding protein p16 may disrupt the formation of the Cdk4/ cyclin D complex and inhibit Cdk4 activity (Serrano et al., 1993), p16 levels do not increase during DNA damage-induced G1-phase checkpoint responses (Shapiro et al., 1998, 2000).”
BackgroundCyclin-dependent Kinases Participate in Death of Neurons Evoked by DNA-damaging Agents
Park, D. S., Morris, E. J., Padmanabhan, J., Shelanski, M. L., Geller, H. M., & Greene, L. A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.457 · Cited by 263
“The coding regions of p16 (Serrano et al., 1993), p21 (Harper et al., 1993), and p27 (Polyak et al., 1994) were subcloned into the BSTEII site of the DSTEQ12 Sindbis virus vector (Joe et al., 1996) downstream of a double subgenomic Sindbis viral promoter.”
BackgroundMethodThe INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 261
“Figure 2 depicts the INK4a/ARF locus and open reading frames of derivative proteins, p16INK4a and p14ARF. p16INK4a was identified initially as a CDK4-associated protein capable of inhibiting CDK4/6-mediated phosphorylation of the retinoblastoma tumor suppressor protein (pRb) (Serrano et al., 1993).”
BackgroundSutherland, R. L., & Musgrove, E. A. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023591.45568.77 · Cited by 258
Molecular prognostic markers in pancreatic cancer: A systematic review
Garcea, G., Neal, C. P., Pattenden, C. J., Steward, W. P., & Berry, D. P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.044 · Cited by 259
“p16 acts as an inhibitor of CDK4 and CDK6, and so plays a key role in controlling the G1 checkpoint in the cell cycle [32].”
BackgroundCell cycle control, checkpoint mechanisms, and genotoxic stress.
Shackelford, R. E., Kaufmann, W. K., & Paules, R. S. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107s15 · Cited by 257
Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.
Kwong, J., Lo, K. W., To, K., Teo, P. M. L., Johnson, P. J., & Huang, D. P. (2002) · PubMed · Cited by 259
MYC Oncogene Contributions to Release of Cell Cycle Brakes
García-Gutiérrez, L., Delgado, M. D., & León, J. (2019) · Genes · doi:10.3390/genes10030244 · Cited by 255
“15 a 16 are characterized for their direct interaction with CDK4 and CDK6, blocking the formation of cyclin D-CDK4/6 complexes and provoking arrested proliferation through preventing p osphorylation f RB and S-phase entry [52].”
BackgroundRole of the retinoblastoma protein in the pathogenesis of human cancer.
Sellers, W. R., & Kaelin, W. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3301 · Cited by 253
Expression of Cyclin-Dependent Kinase Inhibitors in Vascular Disease
Tanner, F. C., Yang, Z.-Y., Duckers, E., Gordon, D., Nabel, G. J., & Nabel, E. G. (1998) · Circulation Research · doi:10.1161/01.res.82.3.396 · Cited by 253
“CKIs directly implicated in CDK regulation are p21,(6,7) p27, and p16/p15.(11) Since cell proliferation is a prominent feature of cardiovascular diseases, including atherosclerosis, angiogenesis, and restenosis, we hypothesized that CKIs regulate G1 progression in VSMCs and function as endogenous inhibitors of VSMC pr…”
BackgroundTassan, J. P., Schultz, S. J., Bartek, J., & Nigg, E. A. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.2.467 · Cited by 251
“These kinases are regulated by multiple mechanisms, including phosphorylation-dephosphorylation (For reviews see Fleig and Gould, 1991; Clarke and Karsenti, 1991; Solomon, 1993; Draetta, 1993), and the binding to other proteins, notably cyclin regulatory subunits (reviewed in Hunt, 1991; Sherr, 1993) and small inhibit…”
BackgroundChemical inhibitors of cyclin-dependent kinases
Meijer, L. (1996) · Trends in Cell Biology · doi:10.1016/0962-8924(96)10034-9 · Cited by 250
p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
Zhu, L., Harlow, E., & Dynlacht, B. D. (1995) · Genes & Development · doi:10.1101/gad.9.14.1740 · Cited by 252
Combinatorial patterns of somatic gene mutations in cancer
Yeang, C.-H., McCormick, F., & Levine, A. (2008) · The FASEB Journal · doi:10.1096/fj.08-108985 · Cited by 251
“CDK4 is inhibited by various proteins, such as TP15, TP16 (18, 19), and TP21.”
Metadata
- Authors
- Serrano, M., Hannon, G. J., & Beach, D.
- Affiliations
- Howard Hughes Medical Institute (US)
- ORCID
- Hannon, Gregory J.
- Venue
- Nature
- Published
- 1993-12
- Volume
- 366
- Issue
- 6456
- Pages
- 704-707
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2066848701
- Cited by
- 3,650
- References
- 22
- Citations by year
- 2026: 36 · 2025: 46 · 2024: 52 · 2023: 66 · 2022: 67 · 2021: 78 · 2020: 64 · 2019: 63 · 2018: 56 · 2017: 70 · 2016: 69 · 2015: 75 · 2014: 52 · 2013: 98 · 2012: 88
- FWCI
- 78.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, CDK4, cyclin D, cyclin-dependent kinases, cell cycle regulation, G1 phase, kinase inhibition, retinoblastoma protein, p21, proliferating cell nuclear antigen, feedback regulation, cell proliferation
- MeSH terms
- Amino Acid Sequence, Base Sequence, Carrier Proteins, Cell Cycle, Cloning, Molecular, DNA, Glutathione Transferase, HeLa Cells, Humans, Molecular Sequence Data, Phosphorylation, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Saccharomyces cerevisiae, Oncogene Proteins, Retinoblastoma Protein, Cyclins, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.